RVMDRevolution Medicines, Inc.

$20B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M-13.2% YoY

Gross Profit

$9M100.0% margin

Operating Income

-$45M-512.0% margin

Net Income

-$44M-509.3% margin

EPS (Diluted)

$-0.60

QoQ Revenue Growth

-14.1%

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$35M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$774M

Total Liabilities

$89M

Stockholders' Equity

$685M

Cash & Equivalents

$196M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$10M	-13.2%
Gross Profit	$9M	$10M	-13.2%
Operating Income	-$45M	-$28M	-59.1%
Net Income	-$44M	-$27M	-62.8%

Revenue Segments

Collaboration Revenue

$9M100%

RVMD Q2 2021 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena